Top Clicks This Month

Not Intended for Therapeutic Use. For research use only.

omega conotoxin MVIIA - CAS 107452-89-1

Quick Inquiry

Name:
* Email:
* Service & Products of Interest:
* Quantity:
* Verification code:
Please input "bocsci" as verification code.
Category
ADCs
Product Name
omega conotoxin MVIIA
Catalog Number
107452-89-1
CAS Number
107452-89-1
Description
ω conotoxin MVIIA (omega conotoxin MVIIA) has been isolated from the venom of the cone Conus magus. Omega-conotoxins act at presynaptic membranes, they bind and block voltage-sensitive calcium channels (VSCC).
Molecular Weight
2639.2
Molecular Formula
C102H172N36O32S7
COA
Inquire
MSDS
Inquire
Tag
ADCs Cytotoxin
Structure
CAS 107452-89-1 omega conotoxin MVIIA
Specification
Purity
97% (HPLC)
Appearance
white powder.
Application
ADCs Cytotoxin
Storage
stable in freeze-dried state. In solution, keep at -20 °C.
Solubility
water, saline.
Related ADCs Cytotoxin Products
  • CAS 59-05-2 Methotrexate

    Methotrexate
    (CAS: 59-05-2)

    Methotrexate(WR19039; CL14377) can interfere with the growth of certain cells of the body, especially cells that reproduce quickly, such as cancer cells, bone m...

  • CAS 95506-56-2 Fasciculin 2

    Fasciculin 2
    (CAS: 95506-56-2)

    Potent, reversible acetylcholinesterase inhibitor

  • Seco-Duocarmycin SA
    (CAS: 152785-82-5)

    Seco-Duocarmycin SA is a cytotoxic agent, used as the cytotoxic component in antibody-drug conjugates.

  • CAS 90332-63-1 10-Deacetyl-7-xylosyl paclitaxel

    10-Deacetyl-7-xylosyl paclitaxel
    (CAS: 90332-63-1)

    10-Deacetyl-7-xylosyl paclitaxel is a Paclitaxel derivative with improved pharmacological features and higher water solubility.

  • Tubulysin M
    (CAS: 936691-46-2)

    Tubulysin M is a Tubulysin D analog with potential anti-cancer properties, used as the cytotoxic component in antibody-drug conjugates.

  • CAS 522-11-2 Evoxine

    Evoxine
    (CAS: 522-11-2)

    Evoxine (haploperine) is a furoquinoline alkaloid with hypnotic and sedative effects. It is found naturally in a variety of Australian and African plants includ...

  • Sanguinarine sulfate
    (CAS: 8006-58-4)

    Sanguinarine is a toxic quaternary ammonium salt from the group of benzophenanthridine alkaloids. It is extracted from some plants, including bloodroot (Sanguin...

  • PBD dimer
    (CAS: 1222490-34-7)

    PBD dimer is a cytotoxic agent, used as the cytotoxic component in antibody-drug conjugates.

  • CAS 90-47-1 Xanthone

    Xanthone
    (CAS: 90-47-1)

    Xanthonoid Purified from Hypericum perforatum

  • CAS 17946-87-1 Leucomisine

    Leucomisine
    (CAS: 17946-87-1)

    Sesquiterpene lactone , from plants of the Compositae family, an antiatherosclerotic, angioprotective, hypolipidemic and anti-inflammatory.

  • CAS 21314-58-9 Triazolone HCl

    Triazolone HCl
    (CAS: 21314-58-9)

    Syntheticquinazolone alkaloid, inhibiting cholinesterase activity in vitro.

  • Donaxine iodomethylate
    (CAS: )

    Donaxine is a naturally occurring indole alkaloid present in several plant species; Analeptic of CNS, tocolytic indole alkaloid Derived from the basic alkaloid ...

  • Benzoylheteratisine hydrochloride
    (CAS: 1262758-10-0)

    A Na+ channel blocker; potent antiarrhythmic, inhibits voltage-gated Na+ channels in rat brain synaptosomes.

  • CAS 6164-47-2 Protopine hydrochloride

    Protopine hydrochloride
    (CAS: 6164-47-2)

    Protopine is a benzylisoquinoline alkaloid occurring in opium poppy, Corydalis tubers and other plants of the family papaveraceae, like Fumaria officinalis. It ...

  • CAS 57345-44-5 NMQ-OAc

    NMQ-OAc
    (CAS: 57345-44-5)

    Bicyclic analog of Ach, a weak muscarinic AChR agonist.

  • CAS 134710-25-1 Calciseptine

    Calciseptine
    (CAS: 134710-25-1)

    Calciseptine is a natural neurotoxin isolated from the black mamba Dendroaspis p. polylepis venom. This toxin consists of 60 amino acids with four disulfide bon...

  • CAS 2752-64-9 Mesaconitine

    Mesaconitine
    (CAS: 2752-64-9)

    Mesaconitine has antinociceptive activity through cyclic AMP and stimulation of the central β-adrenergic system.

  • CAS 220355-66-8 Saxitoxin diacetate

    Saxitoxin diacetate
    (CAS: 220355-66-8)

    Saxitoxin (STX) is a potent neurotoxin and the best-known paralytic shellfish toxin (PST). Ingestion of saxitoxin, usually by consumption of shellfish contamina...

  • CAS 23541-50-6 Daunorubicin Hydrochloride

    Daunorubicin Hydrochloride
    (CAS: 23541-50-6)

    Daunorubicin Hcl inhibits both DNA and RNA synthesis and inhibits DNA synthesis with Ki of 0.02 μM.

  • CAS 50-98-6 (-)-Ephedrine hydrochloride

    (-)-Ephedrine hydrochloride
    (CAS: 50-98-6)

    alpha and beta Adrenoreceptors subtypes agonist; MAO inhibitor. Alkaloid derivative of l-Ephedrine from plants of the Ephedra genus, Ephedraceae.

Reference Reading
1.Clinical Uses of Intrathecal Therapy and Its Placement in the Pain Care Algorithm.
Pope JE1, Deer TR2, Bruel BM3, Falowski S4. Pain Pract. 2016 Feb 23. doi: 10.1111/papr.12438. [Epub ahead of print]
Intrathecal drug delivery is an effective treatment option for patients with severe chronic pain who have not obtained adequate analgesia from more conservative therapies (eg, physical therapy, systemic opioids, nonsteroidal anti-inflammatory drugs, antidepressants, and anticonvulsants). This review focuses on, but is not limited to, the 2 agents currently approved by the U.S. Food and Drug Administration for intrathecal analgesia: preservative-free morphine and ziconotide (a nonopioid, selective N-type calcium channel blocker). We describe the appropriate use of intrathecal therapy in the management of severe chronic pain, based on current best practices. Topics addressed here include patient selection, trialing, dosing and titration, adverse event profiles, long-term management, intrathecal therapy for cancer-related pain, and the placement of intrathecal therapy in the pain care algorithm. In appropriately selected patients with chronic pain, intrathecal therapy can provide substantial pain relief with improved functioning and quality of life.
2.Intrathecal Ziconotide: Dosing and Administration Strategies in Patients With Refractory Chronic Pain.
McDowell GC 2nd1, Pope JE2. Neuromodulation. 2016 Feb 9. doi: 10.1111/ner.12392. [Epub ahead of print]
INTRODUCTION: Ziconotide is a non-opioid analgesic for intrathecal (IT) administration. The aim of this review is to provide a comprehensive and clinically relevant summary of the literature on dosing and administration with IT ziconotide in the management of refractory chronic pain, and to describe novel dosing strategies intended to improve clinical outcomes.
3.ZiconotideMonotherapy: A Systematic Review of Randomised Controlled Trials.
Brookes ME1, Eldabe S, Batterham A. Curr Neuropharmacol. 2016 Feb 10. [Epub ahead of print]
INTRODUCTION: Chronic neuropathic pain is difficult to treat and is often refractory to most modalities of treatment. Ziconotide is a novel, potent, non-opioid, calcium channel blocking agent which has been shown in clinical trials to be effective in treating chronic neuropathic pain.
4.Delivery of ziconotide to cerebrospinal fluid via intranasal pathway for the treatment of chronic pain.
Manda P1, Kushwaha AS1, Kundu S2, Shivakumar HN3, Jo SB1, Murthy SN4. J Control Release. 2016 Feb 28;224:69-76. doi: 10.1016/j.jconrel.2015.12.044. Epub 2015 Dec 28.
The purpose of the current study was to investigate the plausibility of delivery of ziconotide to the cerebrospinal fluid (CSF) via intranasal administration. Ziconotide was administered either in the form of solution or Kolliphor P 407 gels (KP 407) intranasally in Sprague-Dawley rats. The effect of incorporation of chitosan in the formulation was also investigated. Time course of drug in the CSF was investigated by collecting CSF from cisterna magna. Pharmacokinetics of ziconotide in CSF following intrathecal and intravenous (i.v.) administration of ziconotide was investigated. Upon intrathecal administration the elimination rate constant of ziconotide in CSF was found to be 1.01±0.34h(-1). The Cmax and Tmax of ziconotide in CSF following intravenous administration were found to be 37.78±6.8ng/mL and ~2h respectively. The time required to attain maximum concentration (Tmax) in CSF was less upon intranasal administration (15min) compared to i.
2005 - BOC Sciences | All rights reserved
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
DOWNLOAD